Stock listing
NASDAQ:ZNTL Zentalis Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of Zentalis Pharmaceuticals, Inc.
Follow Zentalis Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ZNTL
$1.36 USD 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- $1.33 – $1.50 USDNov 20, 2026
- Volume
- 1.46M sharesNov 20, 2026
- Market cap
- $133.6M USDAt the close on Nov 20, 2026 · price × 98.27M shares outstanding
- 52-week range
- $1.28 – $6.95 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3.18M USDMedian day 1.17M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ZNTL · Home | $1.36 USD | 0.00 (0.0%) | 1,462,135 | $1.33 | $1.50 | $1.33 | $1.36 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ZNTL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.36 | 0.00 | 0.0% | $1.33 | $1.50 | $1.33 | 1,462,135 | |
| $1.36 | -0.13 | -8.7% | $1.50 | $1.52 | $1.36 | 1,209,342 | |
| $1.49 | -0.11 | -6.9% | $1.62 | $1.68 | $1.48 | 1,294,839 | |
| $1.60 | -0.10 | -5.9% | $1.73 | $1.80 | $1.58 | 1,448,149 | |
| $1.70 | +0.02 | +1.2% | $1.68 | $1.76 | $1.63 | 1,299,521 | |
| $1.68 | -0.21 | -11.1% | $1.87 | $1.91 | $1.64 | 1,624,727 | |
| $1.89 | +0.09 | +5.0% | $1.83 | $1.975 | $1.81 | 1,355,953 | |
| $1.80 | +0.06 | +3.4% | $1.94 | $1.975 | $1.775 | 2,560,134 | |
| $1.74 | +0.02 | +1.2% | $1.74 | $1.81 | $1.66 | 1,273,693 | |
| $1.72 | +0.01 | +0.6% | $1.72 | $1.825 | $1.71 | 1,294,167 | |
| $1.71 | -0.05 | -2.8% | $1.75 | $1.82 | $1.63 | 1,641,166 | |
| $1.76 | -0.02 | -1.1% | $1.86 | $1.89 | $1.73 | 1,115,618 | |
| $1.78 | -0.07 | -3.8% | $1.84 | $1.96 | $1.745 | 1,271,091 | |
| $1.85 | -0.11 | -5.6% | $1.95 | $1.99 | $1.83 | 889,758 | |
| $1.96 | -0.03 | -1.5% | $1.99 | $1.99 | $1.86 | 1,332,472 | |
| $1.99 | -0.07 | -3.4% | $2.06 | $2.11 | $1.97 | 1,446,156 | |
| $2.06 | +0.08 | +4.0% | $2.008 | $2.095 | $1.98 | 2,204,705 | |
| $1.98 | -0.09 | -4.3% | $2.07 | $2.118 | $1.96 | 1,721,943 | |
| $2.07 | -0.14 | -6.3% | $2.21 | $2.215 | $2.03 | 1,044,257 | |
| $2.21 | -0.20 | -8.3% | $2.41 | $2.41 | $2.18 | 947,100 | |
| $2.41 | +0.05 | +2.1% | $2.33 | $2.43 | $2.29 | 745,800 | |
| $2.36 | -0.03 | -1.3% | $2.36 | $2.47 | $2.34 | 1,207,000 | |
| $2.39 | +0.09 | +3.9% | $2.31 | $2.44 | $2.25 | 1,557,100 | |
| $2.30 | +0.17 | +8.0% | $2.33 | $2.356 | $2.07 | 2,736,400 | |
| $2.13 | -0.11 | -4.9% | $2.25 | $2.30 | $2.10 | 1,101,800 | |
| $2.24 | -0.08 | -3.4% | $2.27 | $2.396 | $2.21 | 2,034,800 | |
| $2.32 | -0.08 | -3.3% | $2.44 | $2.45 | $2.30 | 865,300 | |
| $2.40 | -0.12 | -4.8% | $2.53 | $2.54 | $2.39 | 570,100 | |
| $2.52 | -0.12 | -4.5% | $2.64 | $2.64 | $2.51 | 546,100 | |
| $2.64 | +0.13 | +5.2% | $2.56 | $2.659 | $2.511 | 612,400 | |
| $2.51 | -0.04 | -1.6% | $2.51 | $2.535 | $2.39 | 1,272,400 | |
| $2.55 | -0.12 | -4.5% | $2.63 | $2.68 | $2.54 | 820,100 | |
| $2.67 | -0.11 | -4.0% | $2.81 | $2.82 | $2.65 | 827,600 | |
| $2.78 | +0.26 | +10.3% | $2.69 | $2.84 | $2.63 | 2,994,700 | |
| $2.52 | -0.085 | -3.3% | $2.64 | $2.65 | $2.495 | 1,451,200 | |
| $2.605 | -0.165 | -6.0% | $2.74 | $2.78 | $2.58 | 1,898,700 | |
| $2.77 | +0.055 | +2.0% | $2.71 | $2.795 | $2.605 | 1,011,500 | |
| $2.715 | +0.115 | +4.4% | $2.62 | $2.81 | $2.57 | 4,779,700 | |
| $2.60 | -0.10 | -3.7% | $2.70 | $2.70 | $2.57 | 1,273,600 | |
| $2.70 | -0.05 | -1.8% | $2.75 | $2.77 | $2.65 | 1,067,400 | |
| $2.75 | -0.12 | -4.2% | $2.84 | $2.89 | $2.73 | 1,173,900 | |
| $2.87 | -0.21 | -6.8% | $3.07 | $3.09 | $2.78 | 1,451,000 | |
| $3.08 | +0.05 | +1.7% | $3.07 | $3.14 | $3.01 | 956,300 | |
| $3.03 | -0.08 | -2.6% | $3.15 | $3.15 | $2.995 | 675,300 | |
| $3.11 | +0.03 | +1.0% | $3.07 | $3.18 | $2.99 | 1,259,700 | |
| $3.08 | -0.02 | -0.6% | $3.18 | $3.215 | $3.02 | 1,088,500 | |
| $3.10 | -0.03 | -1.0% | $3.23 | $3.26 | $3.035 | 1,225,800 | |
| $3.13 | -0.37 | -10.6% | $3.51 | $3.51 | $3.12 | 1,398,600 | |
| $3.50 | -0.01 | -0.3% | $3.47 | $3.57 | $3.44 | 750,400 | |
| $3.51 | -0.08 | -2.2% | $3.63 | $3.67 | $3.465 | 787,700 | |
| $3.59 | -0.21 | -5.5% | $3.74 | $3.765 | $3.555 | 863,100 | |
| $3.80 | -0.23 | -5.7% | $3.99 | $4.039 | $3.79 | 780,400 | |
| $4.03 | +0.04 | +1.0% | $4.00 | $4.10 | $3.885 | 519,200 | |
| $3.99 | -0.12 | -2.9% | $4.05 | $4.185 | $3.92 | 997,800 | |
| $4.11 | +0.34 | +9.0% | $3.80 | $4.12 | $3.73 | 1,366,500 | |
| $3.77 | +0.06 | +1.6% | $3.68 | $3.88 | $3.68 | 897,800 | |
| $3.71 | -0.05 | -1.3% | $3.68 | $3.74 | $3.55 | 863,800 | |
| $3.76 | -0.04 | -1.1% | $3.79 | $3.79 | $3.67 | 471,800 | |
| $3.80 | -0.08 | -2.1% | $3.88 | $3.89 | $3.72 | 695,400 | |
| $3.88 | -0.01 | -0.3% | $3.87 | $3.92 | $3.82 | 430,100 | |
| $3.89 | +0.01 | +0.3% | $3.87 | $3.93 | $3.83 | 576,200 | |
| $3.88 | +0.12 | +3.2% | $3.78 | $3.89 | $3.78 | 799,148 | |
| $3.76 | -0.065 | -1.7% | $3.84 | $3.96 | $3.75 | 988,680 | |
| $3.825 | -0.015 | -0.4% | $3.95 | $3.95 | $3.815 | 740,800 | |
| $3.84 | +0.02 | +0.5% | $4.015 | $4.04 | $3.78 | 1,570,900 |
- Ticker
- NASDAQ:ZNTL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates
Latest deck · Nov 9, 2026
Investor Presentation (November 2026)
Investor deck · 25 slides
Latest news
Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates
Nov 9, 2026
Closed $1.80 (+3.4%) on Nov 10, 2026
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Nov 3, 2026
Closed $1.76 (-1.1%) on Nov 4, 2026
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 2, 2026
Closed $1.78 (-3.8%) on Nov 3, 2026
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
Oct 23, 2026
Closed $2.21 (-8.3%) on Oct 23, 2026
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
Oct 18, 2026
Closed $2.30 (+8.0%) on Oct 19, 2026
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Aug 18, 2026
Closed $3.68 (-0.7%) on Aug 18, 2026
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
Aug 13, 2026
Closed $3.56 (-14.2%) on Aug 14, 2026
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
Aug 13, 2026
Closed $3.56 (-14.2%) on Aug 14, 2026
Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates
Aug 6, 2026
Closed $4.22 (-15.6%) on Aug 7, 2026
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
Jul 17, 2026
Closed $5.01 (-2.0%) on Jul 20, 2026
Zentalis Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 24 in the last 12 months · 115 in all · newest Nov 9, 2026 · oldest 2020
- Decks
- 24 decks · latest Nov 9, 2026
Where Zentalis Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ZNTL · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ZNTL | BOATS | United States | USD |
Valuation
Price/book 0.7× against a median of 2.2×: 2nd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$62.81M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.2×
- Beta vs S&P 500
- 1.44
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. · NASDAQ:ZNTL | US$133.6M | −US$62.81M | n/a | n/a | n/a | 0.7× | n/a | 0.2× | 1.44 |
| VISEN Pharmaceuticals · HKEX:2561 | US$140.7M | US$91.39M | n/a | 29.9× | n/a | 1.4× | n/a | 0.3× | n/a |
| Protara Therapeutics, Inc. · NASDAQ:TARA | US$140.4M | US$15.77M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 1.12 |
| Cloudbreak Pharma, Inc. · HKEX:2592 | US$140.4M | US$82.02M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | n/a |
| Scancell Holdings PLC · LSE:SCLP | US$140.2M | US$155.6M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Abeona Therapeutics Inc. · NASDAQ:ABEO | US$138.4M | US$15.29M | n/a | 0.4× | n/a | 1.1× | −160.3% | 0.1× | 1.00 |
| DX & VX Co., Ltd. · KRX:180400 | US$134.6M | US$100.6M | n/a | 5.1× | n/a | 2.2× | −99.2% | 0.1× | n/a |
| Starpharma Holdings Limited · ASX:SPL | US$133.4M | US$126.5M | n/a | 15.9× | n/a | 14.6× | −62.0% | 0.1× | n/a |
| Sionna Therapeutics, Inc. · NASDAQ:SION | US$127.8M | −US$89.05M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.51 |
| IntoCell, Inc. · KRX:287840 | US$127.3M | US$109.4M | n/a | 45.9× | n/a | 8.7× | −295.9% | 0.0× | n/a |
| Yoda Pharmaceuticals Inc. · TPEX:7829 | US$127.1M | US$94.39M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | n/a |
| Median of the others | US$136.5M | US$92.89M | 15.9× | 2.2× | −129.7% | 0.0× | 1.12 |
Forecasts
8 strong buy · 3 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.33 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.74 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Julie Eastland | Chief Executive Officer and Director |
| Vincent Vultaggio | Senior Vice President, Finance & Principal Accounting Officer |
| James Bucher | Chief Legal Officer and Corporate Secretary |
| Aron Feingold | VP, Investor Relations & Corporate |
| Henry Gu | Senior Vice President, Head of Intellectual Property |
| Rajesh Israni | Executive Vice President, Regulatory Affairs & Medical Writing |
| Sarah Kelly | Senior Vice President, Commercial Strategy |
| Susan Saffle | Senior Vice President, Information Technology |
| Haibo Wang | Chief Business Officer |
| Ingmar Bruns | Chief Medical Officer |
| Robert DiVasto | Chief Technical Officer |
| Wendy Chang | Chief People Officer |
Board
| Director | Role |
|---|---|
| Scott Myers | Chairperson |
| Dave Johnson | |
| Enoch Kariuki | Director |
| Jan Skvarka | Director |
| Julie Eastland | Chief Executive Officer and Director |
| Luke Walker | Director |
| Shannon Campbell | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · After close | +3.5% |
| Q2 2026 | Aug 6, 2026 · After close | −15.6% |
| Q1 2026 | May 13, 2026 | −4.4% |
| Q4 2025 | Mar 26, 2026 · After close | −21.4% |
| Q3 2025 | Nov 10, 2025 · After close | +6.1% |
| Q2 2025 | Aug 6, 2025 · After close | +5.1% |
| Q1 2025 | May 14, 2025 · After close | +5.9% |
| Q4 2024 | Feb 25, 2025 · Before open | −4.7% |
| Q3 2024 | Nov 12, 2024 · After close | +5.7% |
| Q2 2024 | Aug 9, 2024 · Before open | −9.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · Before open | +5.0% |
| Q4 2023 | Feb 27, 2024 · Before open | +4.5% |
| Q3 2023 | Nov 6, 2023 · Before open | −30.2% |
| Q2 2023 | Aug 9, 2023 · Before open | +0.7% |
| Q1 2023 | May 10, 2023 · Before open | +6.9% |
| Q4 2022 | Mar 1, 2023 · Before open | −0.3% |
| Q3 2022 | Nov 9, 2022 · Before open | −22.0% |
| Q2 2022 | Aug 9, 2022 · After close | +1.1% |
| Q1 2022 | May 5, 2022 · Before open | −6.7% |
| Q4 2021 | Feb 24, 2022 · Before open | +6.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 25 slides | Nov 9, 2026 |
| Investor Presentation (August 2026) | Investor deck | 29 slides | August 2026 |
| Investor Presentation (May 2026) | Investor deck | 29 slides | May 12, 2026 |
| Investor Presentation (April 2026) | Investor deck | 39 slides | Apr 9, 2026 |
| Investor Presentation (January 2026) | Investor deck | 40 slides | Jan 9, 2026 |
| Investor Presentation (November 2025) | Investor deck | 37 slides | Nov 10, 2025 |
| Investor Presentation (August 2025) | Investor deck | 37 slides | Aug 6, 2025 |
| SGO Annual Meeting on Women's Cancer 2025 | Conference | 14 slides | Mar 17, 2025 |
| Corporate Update (January 2025) | Corporate update | 45 slides | Jan 29, 2025 |
| Investor Presentation (June 2024) | Investor deck | 61 slides | Jun 3, 2024 |
All 24 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (April 2024) | Investor deck | 55 slides | Apr 9, 2024 |
| Investor Presentation (November 2023) | Investor deck | 55 slides | Nov 6, 2023 |
| Investor Presentation (September 2023) | Investor deck | 43 slides | Sep 13, 2023 |
| Investor Presentation (August 2023) | Investor deck | 47 slides | Aug 9, 2023 |
| Corporate Update (June 2023) | Corporate update | 53 slides | Jun 6, 2023 |
| Investor Presentation (June 2023) | Investor deck | 47 slides | Jun 6, 2023 |
| Investor Presentation (April 2023) | Investor deck | 55 slides | Apr 17, 2023 |
| Investor Presentation (March 2023) | Investor deck | 53 slides | Mar 1, 2023 |
| Investor Presentation (January 2023) | Investor deck | 56 slides | Jan 9, 2023 |
| Investor Presentation (November 2022) | Investor deck | 56 slides | Nov 9, 2022 |
| Investor Presentation (August 2022) | Investor deck | 44 slides | Aug 9, 2022 |
| Investor Day (April 2022) | Investor day | 55 slides | Apr 8, 2022 |
| Technical Presentation (2022) | Technical | 19 slides | 2022 |
| Corporate Update (June 2021) | Corporate update | 44 slides | Jun 28, 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$92.6M raised · US$3.5 a share · TD Cowen +4 Dealers: TD Cowen (co-lead), Guggenheim Securities (co-lead), Oppenheimer & Co. (co-lead), H.C. Wainwright & Co., Rodman & Renshaw LLC Use of proceeds: Fund clinical trials, preclinical studies, regulatory filings, manufacturing, companion diagnostic, pre-commercial activities, working capital and general purposes | Aug 18, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 a share on Apr 2, 2020.
- Price
- US$18.00 a share
- Shares offered
- 9,180,000 shares of common stock
- Offering size
- US$165.2 million
- Underwriters' option
- Up to 1,377,000 more shares
- Underwriters
- Morgan Stanley, Jefferies, SVB Leerink, Guggenheim Securities · In the order on the cover
- Shares delivered
- On or about Apr 7, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jan 8, 2020 |
| Filed publicly | Mar 6, 2020 |
| Amended twice | Newest Mar 31, 2020 |
| Shares registered with an exchange | Apr 2, 2020 |
| Declared effective by the SEC | Apr 2, 2020 |
| Final prospectus, with the price | Apr 6, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Apr 6, 2020 |
| CERT · Exchange's certificate of listing | Apr 3, 2020 |
| EFFECT · Notice that a registration is effective | Apr 2, 2020 |
| S-1MEF · Registration of more shares for the same offering | Apr 2, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 2, 2020 |
| CORRESP · Letter to the SEC | Mar 31, 2020 |
| CORRESP · Letter to the SEC | Mar 31, 2020 |
| S-1/A · Registration statement, amended | Mar 31, 2020 |
| S-1/A · Registration statement, amended | Mar 30, 2020 |
| CORRESP · Letter to the SEC | Mar 13, 2020 |
All 17 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Mar 13, 2020 |
| UPLOAD · Letter from the SEC | Mar 11, 2020 |
| S-1 · Registration statement | Mar 6, 2020 |
| DRSLTR · Letter to the SEC with a draft | Feb 14, 2020 |
| DRS/A · Draft registration statement, amended | Feb 14, 2020 |
| UPLOAD · Letter from the SEC | Feb 11, 2020 |
| DRS · Draft registration statement | Jan 8, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Apr 6, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 67.4M | 0 | 0 | 0 | 0 | 0 | 14.0K |
| Cost of revenue | 739.0K | 1.29M | 1.39M | 1.43M | 544.0K | 160.0K | 111.0K | |
| Gross profit | -739.0K | 67.4M | -1.39M | -1.43M | -544.0K | -160.0K | -111.0K | 14.0K |
| Research and development | 107.3M | 167.8M | 189.6M | 172.7M | 175.6M | 84.9M | 38.4M | 18.9M |
| Selling, general and administrative | 37.7M | 87.1M | 59.4M | 54.6M | 40.9M | 33.9M | 8.46M | 4.88M |
| Operating income | -152.8M | -191.2M | -299.5M | -227.3M | -216.5M | -118.8M | -46.8M | -23.8M |
| Depreciation and amortization | 739.0K | 1.29M | 1.39M | 1.43M | 544.0K | 160.0K | 111.0K | 51.0K |
| EBITDA | -152.1M | -189.9M | -298.1M | -225.9M | -216.0M | -118.6M | -46.7M | -23.7M |
| Interest expense | 2.58M | 110.0M | 2.23M | 1.20M | 0 | |||
| Income before tax | -136.6M | -165.7M | -292.9M | -237.6M | -166.4M | -118.1M | -46.4M | -23.4M |
| Income tax | 442.0K | 177.0K | -601.0K | -469.0K | -297.0K | 444.0K | 15.0K | 4.00K |
| Net income | -137.1M | -165.8M | -292.2M | -236.8M | -158.7M | -117.8M | -45.7M | -21.1M |
| Earnings per share, basic | -1.91 | -2.33 | -4.47 | -4.48 | -3.72 | -4.19 | -0.77 | -1.17 |
| Earnings per share, diluted | -1.91 | -2.33 | -4.47 | -4.48 | -3.72 | -4.19 | -8.16 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 36.0M | 33.9M | 28.0M | 43.1M | 59.7M | 55.0M | 67.2M | 25.2M |
| Short-term investments | 209.9M | 318.0M | 454.9M | 394.3M | 280.2M | 283.6M | ||
| Receivables | 0 | 5.00M | 0 | 7.04M | 4.00K | 417.0K | 140.0K | 917.0K |
| Inventory | -7.04M | -4.44M | ||||||
| Current assets | 253.2M | 386.1M | 496.7M | 451.9M | 350.8M | 345.1M | 68.9M | 26.7M |
| Property, plant and equipment | 2.77M | 4.70M | 5.82M | 7.71M | 8.15M | 1.10M | 501.0K | 260.0K |
| Goodwill | 0 | 3.74M | 3.74M | 3.74M | 3.74M | 3.74M | 3.74M | |
| Total assets | 289.0M | 430.3M | 551.7M | 539.3M | 454.5M | 365.6M | 87.5M | 41.0M |
| Accounts payable | 7.21M | 7.44M | 14.9M | 11.2M | 11.6M | 8.66M | 4.29M | 3.43M |
| Current liabilities | 36.6M | 52.7M | 69.4M | 56.6M | 43.9M | 28.6M | 14.9M | 6.21M |
| Total debt | 39.6M | 42.6M | 45.8M | 47.3M | 45.9M | 2.00M | 2.48M | |
| Total liabilities | 72.8M | 93.2M | 114.3M | 105.3M | 90.0M | 32.2M | 19.1M | 8.69M |
| Shareholders' equity | 216.2M | 337.2M | 437.3M | 433.8M | 364.0M | 308.6M | -73.3M | 24.8M |
| Shares outstanding | 69.1M | 71.3M | 70.8M | 59.3M | 45.5M | 41.0M | 59.4M | 18.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -125.2M | -170.9M | -207.8M | -163.8M | -154.1M | -86.8M | -39.1M | -24.3M |
| Capital spending | 0 | -221.0K | -583.0K | -2.55M | -6.11M | -758.0K | -352.0K | -227.0K |
| Free cash flow | -125.2M | -171.1M | -208.4M | -166.3M | -160.2M | -87.6M | -39.5M | -24.5M |
| Cash from investing | 131.6M | 176.6M | -44.5M | -114.2M | -18.1M | -284.8M | -352.0K | -227.0K |
| Cash from financing | -4.28M | 108.0K | 237.3M | 261.0M | 178.5M | 360.4M | 81.8M | 9.47M |
| Share buybacks | -9.98M | 0 | 0 | 261.0M | -1.15K | 346.2M | 81.9M | 9.47M |
| Change in cash | 2.09M | 5.81M | -15.0M | -16.9M | 6.31M | -11.2M | 42.3M | -15.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 1, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 19, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 14, 2026 | Current report | SEC |
| 424B5 · Prospectus | Aug 14, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 424B5 · Prospectus | Aug 13, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 27, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | May 27, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 27, 2026 | Management or board change | SEC |
| 8-K · Current report | May 21, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 8-K · Current report | May 5, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| 8-K · Current report | Apr 17, 2026 | Current report | SEC |
| 8-K · Current report | Apr 9, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 3, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 8, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 2, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 15, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 26, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 2, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | May 23, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 20, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | May 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 30, 2025 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 30, 2025 | Annual report | SEC |
| 8-K · Current report | Apr 28, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Apr 7, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 2, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 1, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 26, 2025 | Results | SEC |
| S-3 · Registration statement | Mar 26, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 26, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 17, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 11, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 4, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 3, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 31, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 31, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 29, 2025 | Current report | SEC |
| 8-K · Current report | Jan 28, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 22, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 8, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 8-K/A · Current report, amended | Dec 19, 2024 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 10, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 13, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 13, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 13, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 6, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Oct 31, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 18, 2024 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Oct 17, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 10, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 7, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 16, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Sep 12, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 9, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 21, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 3, 2024 | Current report | SEC |
| 144 · Notice of proposed sale | May 31, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 29, 2024 | Insider trade | SEC |
| DEFA14A · Additional proxy material | May 29, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 29, 2024 | Management or board change | SEC |
| 144 · Notice of proposed sale | May 9, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 9, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| 3 · Initial statement of ownership | Apr 11, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 11, 2024 | Management or board change | SEC |
| 8-K · Current report | Apr 9, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Feb 29, 2024 | Offer document | SEC |
| S-3ASR · Registration statement | Feb 29, 2024 | Offer document | SEC |
| 10-K · Annual report | Feb 27, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2024 | Results | SEC |
| 8-K · Current report | Feb 15, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 12, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 12, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 12, 2024 | Other filings | SEC |
| 4 · Change in ownership | Feb 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 2, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 29, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 25, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 25, 2024 | Management or board change | SEC |
| 8-K · Current report | Jan 8, 2024 | Current report | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 21, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Dec 11, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 17, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 6, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2023 | Results | SEC |
| SC 13G · Big-stake notice | Oct 10, 2023 | Big-stake notice | SEC |
This page holds 200 of 550 filings. Open Filings
Cap table
Built by 6ix from Zentalis Pharmaceuticals, Inc.’s releases · as of Nov 4, 2026
- Common shares
- 98,265,863
- Fully diluted
- 98,265,863
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 98,265,863 | Nov 4, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 4, 2026 | 98,265,863 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Julia Marie Eastland Other companies: Lantheus Holdings, Inc. (Director · Since at least Sep 3, 2024); CalciMedica, Inc. (Director · Jun 2, 2021 – Mar 23, 2023 · Past); Dynavax Technologies Corporation (Director · May 28, 2021 – May 23, 2024 · Past); Harpoon Therapeutics Inc (President and CEO, Director · May 4, 2021 – Mar 11, 2024 · Past) | CEO & President, Director · Since at least Nov 13, 2024 |
| David Johnson Other companies: Aura Biosciences, Inc. (Director · Since at least May 4, 2026); Dynavax Technologies Corporation (Vice President · Jun 2, 2019 – Mar 13, 2020 · Past) | Director · Since at least Jun 16, 2026 |
| James B. Bucher Other companies: Harpoon Therapeutics Inc (Chief Legal Officer · Dec 21, 2023 – Mar 11, 2024 · Past); Climb Bio, Inc. (EVP and General Counsel · Oct 31, 2022 – Oct 31, 2022 · Past) | Chief Legal Officer and Corporate Secretary · Since at least Aug 26, 2025 |
| Kimberly Blackwell Other companies: Century Therapeutics, Inc. (Director · Since at least Jun 17, 2021); Monte Rosa Therapeutics, Inc. (Chief Development Officer, Nucleus RadioPharma · Since at least Apr 12, 2021) | Chief Executive Officer, Director · Jul 1, 2020 – Feb 1, 2024 · Past |
| Luke Walker Other companies: Context Therapeutics Inc. (Director · Since at least Sep 4, 2024); Harpoon Therapeutics Inc (Chief Medical Officer · Oct 3, 2022 – Mar 11, 2024 · Past) | Director · Since at least May 24, 2024 |
| Cam Gallagher Other companies: Opus Genetics, Inc. (Director · Since at least Jun 11, 2024) | President, Interim CFO, Director · Feb 1, 2024 – May 31, 2024 · Past |
| Enoch Kariuki Other companies: Imago Biosciences Inc (Director · Jul 15, 2021 – Jan 11, 2023 · Past) | Director · Since at least Feb 9, 2021 |
| Jan Skvarka Other companies: Monte Rosa Therapeutics, Inc. (Executive Chairman, DEM Biopharma · Since at least Nov 4, 2026) | Director · Since at least Jun 18, 2026 |
| Julie Eastland Other companies: Lantheus Holdings, Inc. (Director · Since at least Feb 26, 2025) | Chief Executive Officer and Director · Since at least Nov 13, 2024 |
| Alexis Pinto | Chief Legal Officer · Aug 31, 2020 – Feb 10, 2022 · Past |
All 24 people
| Person | Seat |
|---|---|
| Aron Feingold | VP, Investor Relations & Corporate · Since at least Oct 1, 2026 |
| Dave Johnson | Director · Since at least Nov 13, 2024 |
| Haibo Wang | Chief Business Officer · Since at least Apr 28, 2025 |
| Henry Gu | Senior Vice President, Head of Intellectual Property · Since at least Nov 4, 2026 |
| Ingmar Bruns | Chief Medical Officer · Since at least Nov 13, 2024 |
| Kevin D Bunker | Chief Scientific Officer · Apr 3, 2020 – Dec 20, 2023 · Past |
| Rajesh Israni | Executive Vice President, Regulatory Affairs & Medical Writing · Since at least Nov 4, 2026 |
| Robert DiVasto | Chief Technical Officer · Since at least Nov 4, 2026 |
| Sarah Kelly | Senior Vice President, Commercial Strategy · Since at least May 27, 2026 |
| Scott Myers | Chairperson · Since at least Nov 13, 2024 |
| Shannon Campbell | Director · Since at least May 26, 2026 |
| Susan Saffle | Senior Vice President, Information Technology · Since at least Nov 4, 2026 |
| Vincent Vultaggio | Senior Vice President, Finance & Principal Accounting Officer · Since at least Nov 4, 2026 |
| Wendy Chang | Chief People Officer · Since at least Dec 12, 2024 |
Log in to ask 6ix AI your own questions about Zentalis Pharmaceuticals, Inc.